IL-22 Administration Protects Intestinal Stem Cells from Gvhd
Caroline A. Lindemans(University Medical Center Utrecht), Alan M. Hanash(Memorial Sloan Kettering Cancer Center), Margaret O'Connor(Memorial Sloan Kettering Cancer Center), Jarrod A. Dudakov(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Richard Kolesnick(Memorial Sloan Kettering Cancer Center), Anna Mertelsmann(University of Zurich), Enrico Velardi(Bambino Gesù Children's Hospital), Guoqiang Hua(Inserm), Marcel R.M. van den Brink(City Of Hope National Medical Center)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2015|762